Research programme: schizophrenia therapeutics - EUSA PharmaAlternative Names: TKP-1002
Latest Information Update: 18 Jun 2012
At a glance
- Originator EUSA Pharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 18 Jun 2012 Discontinued - Preclinical for Schizophrenia in United Kingdom (unspecified route)
- 09 Oct 2007 Preclinical trials in Schizophrenia in United Kingdom (unspecified route)
- 09 Oct 2007 EUSA Pharma is seeking partnership/divestment opportunities for TKP 1002 in Schizophrenia (http://www.eusapharma.com)